La Crema De Rebeca - 728782 - 05/14/2026

Why It Matters

The enforcement highlights serious consumer‑health risks from mercury‑containing products and reinforces FDA’s crackdown on unapproved, misbranded drugs sold online, protecting public safety and market integrity.

Key Takeaways

• FDA found high mercury levels in La Crema De Rebeca cream
• Product classified as an unapproved new drug under FD&C Act
• Label omitted mercury content, rendering it misbranded
• Mercury exposure can cause kidney and neurological damage
• Company must respond within 15 business days or face action

Pulse Analysis

The FDA’s warning to La Crema De Rebeca underscores the agency’s broad authority to regulate products that cross the line from cosmetics into drugs. While skin‑lightening creams are often marketed as cosmetics, claims that they treat acne, melasma, or other skin conditions trigger the drug definition under the FD&C Act. By positioning the cream as a therapeutic solution, the company invited FDA scrutiny and, after testing, was found to be distributing an unapproved new drug—a violation that can lead to immediate market removal and civil penalties.

Mercury has a long, troubled history in personal‑care products. The FDA banned mercury‑containing cosmetics in 1970, yet some manufacturers still use it for its skin‑lightening properties, exposing users to neurotoxic and nephrotoxic effects. Chronic dermal absorption can elevate blood mercury levels, posing heightened risks to children, pregnant women, and individuals with pre‑existing kidney conditions. Recent studies link such exposure to irreversible neurological damage, reinforcing why regulators treat undisclosed mercury as a public‑health emergency.

For e‑commerce sellers and niche beauty brands, the letter serves as a cautionary tale. Companies must conduct rigorous ingredient testing, ensure labeling transparency, and secure proper drug approvals before making therapeutic claims. Non‑compliance not only jeopardizes consumer safety but also threatens brand reputation and can result in costly recalls or legal action. Proactive compliance programs, third‑party lab verification, and clear distinction between cosmetic and drug claims are essential steps to maintain market access and consumer trust.